Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.

@article{Godwin1995DesignAC,
  title={Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.},
  author={John E Godwin},
  journal={Journal of the National Cancer Institute. Monographs},
  year={1995},
  volume={19},
  pages={31-5}
}
  • John E Godwin
  • Published 1995 in
    Journal of the National Cancer Institute…
From the public health standpoint, acute myeloid leukemia (AML) is an important problem for both young and older adults. AML is the leading cause of cancer death in men aged 15-34 years and the second leading cause of cancer death in women in this age group. This clearly has an impact on loss of life in the productive years. But in terms of the population… CONTINUE READING